0.10
-0.0269(-21.40%)
Currency In USD
Address
601 Gateway Blvd
South San Francisco, CA 94080
United States of America
Phone
415 910 5717
Website
Sector
Healthcare
Industry
Biotechnology
Employees
36
First IPO Date
May 09, 2019
| Name | Title | Pay | Year Born |
| Dirk Thye | Chief Executive Officer, Chief Medical Officer & Director | 767,125 | 1970 |
| Brendan Hannah | Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer | 579,875 | 1986 |
| Charles S. Ryan | President | 703,100 | 1964 |
| Guenter R. Janhofer | Chief Scientific Officer | 0 | N/A |
| Stewart A. Low | Head of Discovery | 0 | N/A |
| Giovanni Mambrini | Chief Technology Officer | 0 | N/A |
| Mary Ellen Sillivos | Vice President of Human Resources | 0 | N/A |
| Pamela Williamson | Head of Regulatory Affairs | 0 | N/A |
| Stacy Roughan | Vice President of Corporate Communications & Investor Relations | 0 | N/A |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.